secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0001104659-23-042255
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Priveterra Acquisition Corp. restates 2022 financials after accounting error on $3.8M underwriter fee waiver
--------------------------------------------------------------------------------

- Company will restate 2022 financial statements due to improper accounting for $3.8M deferred underwriter commission waiver.
- Material weakness identified in internal control over financial reporting; disclosure controls ineffective.
- Restatement does not affect liquidity, cash flows, or operating expenses for the period.
- Amendment No. 1 to Form 10-K to be filed with revised risk factors, MD&A, and financial statements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923042255/0001104659-23-042255-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923042255/tm2311853d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-042255

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer